Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating
osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12
months followed by 12 months treatment with risedronate.